(Credit-Canva)
Headaches are a common symptom of a stressful lifestyle, your body not feeling well and other issues. While headaches can be dealt with easily, migraines are not so easy to handle. Migraines are a type of headache that feels like severe throbbing and pulsing sensation, almost like you are hearing your own heartbeat in your brain, usually on one side of the brain. Many people believe that migraines are not that big of a deal because you just have to deal with the pain, but that is not all migraine is, some people find it very difficult to do their daily tasks as they experience dizzying spells, nausea and extreme sensitivity to light and sound! These attacks can last hours and make it difficult for people to go about their daily lives as well. While there are medications available for migraine patients, these medications need time to take effect, so you may be in a lot of pain, but there are not many quick reliefs you can have in place other than learning the symptoms of a migraine attack and taking medication before it happens. But a new approval by the FDA may change this!
The U.S. Food and Drug Administration (FDA) has approved Symbravo, a new medicine to treat acute migraine attacks in adults. This means adults can now use Symbravo to get relief from their migraine symptoms. The FDA's decision was based on the results of three big studies, called Phase 3 trials. These trials involved over 21,000 migraine attacks, so the FDA has a lot of information about how well Symbravo works and how safe it is. The FDA only approves medicines that have been shown to be both safe and effective through a thorough testing process.
"Migraine attacks can happen suddenly and really mess up people's lives. It's estimated that over 39 million people in the U.S. alone get migraines," said Herriot Tabuteau, M.D., CEO of Axsome Therapeutics told US News. This shows how common migraines are and how important it is to have good treatments. "Symbravo gives patients and doctors a new option that can quickly stop a migraine attack, keep it away, and let people get back to their normal activities, all with just one dose." Having a medicine that can give fast and long-lasting relief from migraine pain is a big deal for millions of people. This new treatment is a real step forward in how we treat migraines.
The trials took place in 3 steps, the Momentum trial study focused on people whose migraines had moderate to severe pain. The results showed that a lot more people taking Symbravo felt pain-free two hours after taking the medicine compared to those who took a placebo which is a dummy pill. Even better, many people felt relief for up to 24 and even 48 hours after just one dose. This long-lasting relief is really important for people with migraines because it means they can get back to their normal lives without worrying about the pain coming back. The study also looked at how many people were free from their worst symptom, like sensitivity to light or sound, or nausea. Symbravo worked better than the placebo in this area too.
While the intercept trial looked at people who took Symbravo when their migraine pain was still mild. Even when the pain was just starting, Symbravo was effective. The results were similar to the MOMENTUM trial, with many people getting pain relief and relief from their worst symptoms. Treating migraines early is often better because it can stop the pain from getting really bad.
And lastly the Movement trial which was to see how safe the medication is when people take it regularly. This study followed 706 people who had at least two migraines a month. The most common side effects people experienced were sleepiness and dizziness. While these side effects are important to know about, the study showed that Symbravo is generally safe for people to use on a regular basis.
Credits: iStock
No more scribbling, notes a BBC report from October 1, 2025, where the Punjab and Haryana court tells doctors to fix their handwriting. Now, the National Medical Commission or NMC has issued nationwide order to the doctors to ensure their prescriptions are written in a clear and legible manner.
While jokes around the notoriously bad handwriting of many doctors that only can be read by pharmacist are common in India, but after the High Court's ruling, this joke is taken seriously. The High Court noted that "legible medical prescription is a fundamental right" as it can make a difference between life and death.
Under the new directive, the NMC ordered that doctors must:

The Punjab and Haryana High Court ordered doctors to fix their handwritings while it was looking at a case that involved allegations of rape. While checking a medico-legal report written by a government doctor who examined the woman, the court found it incomprehensible.
Justice Jasgurpreet Singh Puri said, "It shook the conscience of this court as not even a word or a letter was legible".
"At a time when technology and computers are easily accessible, it is shocking that government doctors are still writing prescriptions by hand which cannot be read by anybody except perhaps some chemists," said Justice Puri.
The World Health Organization (WHO) identifies medication errors as a major global patient safety challenge, contributing to avoidable injuries and deaths worldwide. Illegible prescriptions are a well-recognised cause of such errors.
Poor handwriting leads to misinterpretation of the intended drug name, dosage, or instructions. Many drugs have names that look or sound alike, making clarity critical.
Unclear instructions when it comes to dosing result in giving out doses that are ten or one hundred times the correct amount, leading to toxicity or therapeutic failure.
When the patients are able to clearly read and understand the prescriptions and medication labels, they are more likely to take their medications correctly, reducing the margin for errors.
Medication errors resulting from unclear prescriptions lead to increased hospital admissions, prolonged lengths of stay, and additional costs, placing a significant burden on the patient and the healthcare system.
Credits: iStock and Canva
Oral cancer cases recorded the sharpest in Delhi in 2025, as per the Union Health Ministry data presented in the Parliament. While there is no definitive explanation provided by the report by the Union Health Ministry, previous reports show that widespread use of tobacco has increased, and accounted for about 30% of all oral cancer cases in India alone.

As per the report shared by the Union Health Ministry, a 5.1% increase was scene in the reported increase of oral cancer, while lung cancer rose by 4.9% between the period 2023 and 2025.
Also Read: ‘Fix Your Handwriting’: Indian Doctors Told to Write Clear, Legible Prescriptions Under New Rules

The data showed that lung cancer increased among women, and it rose to 6.5%. In numbers, this would make 686 cases in 2025, which is up from the 644 cases recorded in 2024, and 604 in 2023. Among men, oral cancer had the highest growth, with a 5.8% increase. This led to 2,717 cases in 2025, compared to 2,569 cases in 2024 and 2,429 cases in 2023.

However, breast cancer remained the most prevalent cancer in the city. Data from the National Cancer Registry Programme indicate a steady rise in reported breast cancer cases, increasing from 3,198 in 2023 to 3,260 in 2024 and 3,321 in 2025. Oral cancer ranked as the second most common cancer overall, with combined cases among men and women reaching 3,208 in 2025.

A closer look at the data shows that oral cancer continued to rise in the city over the past three years. In 2023, Delhi reported 2,901 cases, including 2,429 among men and 472 among women. The number rose to 3,051 cases in 2024, with 2,569 cases in men and 482 in women. Among women, cases increased slightly further to 491 in 2025.
The International Journal of Research in Medical Sciences provide the tobacco use, betel quid chewing has seen a rising trend in India. Tobacco use includes chewing gutka and khaini in rural areas as well as smoking cigarettes in urban area, which continues to be the nation's leading preventable cause of cancer.
Cervical cancer followed a different pattern. Cases among women fell from 741 in 2023 to 716 in 2024, and then to 692 in 2025. This reflects a year-on-year decline of around 3.4 percent over both periods.
Among men, oral cancer showed the sharpest increase. Lung cancer cases also rose, climbing from 1,668 in 2023 to 1,814 in 2025. Prostate cancer followed a similar upward trend, with reported cases increasing from 1,168 in 2023 to 1,301 in 2025.
The health ministry has pointed to Delhi’s relatively high Age-Adjusted Incidence Rate of cancer. Between 2015 and 2019, the AAIR stood at 146.7 per one lakh population among men and 132.5 among women. These figures are higher than those reported in cities such as Mumbai, Kolkata, Pune and Ahmedabad. The AAIR allows cancer rates to be compared fairly across regions with different age profiles.
It is also important to note that Delhi attracts a large number of cancer patients from across north India and other parts of the country. Major tertiary care centres, including AIIMS and the Rajiv Gandhi Cancer Institute and Research Centre, contribute to a higher treatment load in the city.
Credits: iStock
Rougeole/Measles: Christmas is not even 10 days away and other festivities are also lining up. With the holiday season coming in, more cases of measles are likely to be added to the five which had already been recorded in Montreal.
"It's certain that the holiday season worries us, because we gather, we meet our families, we have more contact, and therefore more opportunities for transmission of the virus," said Dr. Paul Le Guerrier on QUB radio and television, broadcast simultaneously on 99.5 FM Montreal, Tuesday.
As per the medical advisor at Montreal's Regional Public Health Department, a surge in cases during this time of the year is conducive as there will be more gathering. In fact, "almost 95% of population would need to be vaccinated to prevent community transmission."
"At the end of secondary school, we reach levels of 86-88%. But we are not yet at the desired threshold," the doctor specifies.
The spread could be curbed and a significant outbreak during the holiday season could be avoided, if vaccination is done in full flow. Public health department has sent letters to all schools in Montreal province. "If children do not have two doses of measles vaccine, [they are encouraged] to make an appointment or go see their family doctor to increase their vaccination coverage," explained Dr. Le Guerrier.
The public is also urged to keep a check of common signs and measles symptoms like:
The Global News reported that so far, Quebec has confirmed three measles cases linked to pediatric medical center in an off-island suburb of Montreal.
The first case was identified in early December, marking the province’s first measles infection since April. Health officials say people who visited the UP pediatric emergency centre in St-Eustache, Que., on the afternoon or evening of Nov. 28 may have been exposed.
So far this year, Canada has reported more than 5,300 measles cases, largely in Ontario and Alberta. Quebec recorded 36 cases during an earlier outbreak. The provincial government warns additional cases are likely and stresses vaccination as the strongest protection against the highly contagious disease.
Measles has a high transmissibility, and high measles immunity levels are required to prevent sustained measles virus transmission. This is why herd immunity for measles could be easily breached.
It easily spreads from one infected person to another through breathes, coughs or sneezes and could cause severe disease, complications, and even death.
Read: Unique Symptoms Of Measles In 2025 And How Long Does The Infection Last?
The most unique symptom or the early sign of measles in the Koplik spots. These are tiny white dots that look like grains of salt on red gums inside the cheeks that appear before the red rash starts to appear on a person's face and then the body.
Furthermore, the symptoms of measles are also characterized by the three Cs:
The progression of the symptom comes in two stages, first is the prodromal stage or Days 1 to 4, where one would notice high fever, cough, runny nose, red and watery eyes, sore throat, fatigue, and Koplik spots.
The second stage is called the rash stage or the days 5 to 10 or even more where rash start to appear on the hairline, and then it runs down the body. It lasts for several days and fades in the same order.
The first symptoms, notes the Centers for Disease Control and Prevention (CDC), appear 7 to 14 days after a measles infection. Often, it could also lead to ear infection, or even diarrhea. Though these complications happen in every 1 in 10 children or individual with measles.
© 2024 Bennett, Coleman & Company Limited